Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 November 17, 2026 Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update Go to November 16, 2026 Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026 Go to November 9, 2026 Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies Go to November 4, 2026 Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders Go to October 26, 2026 Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease Go to October 22, 2026 Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference Go to Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
November 17, 2026 Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update Go to
November 16, 2026 Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026 Go to
November 9, 2026 Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies Go to
November 4, 2026 Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders Go to
October 26, 2026 Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease Go to
October 22, 2026 Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference Go to